ispronicline

Ispronicline is an experimental small molecule drug that acts as a subtype-selective partial agonist at neural nicotinic acetylcholine receptors, primarily targeting the α4β2 subtype. It was developed for central nervous system (CNS) indications and has demonstrated antidepressant, nootropic (cognition-enhancing), and neuroprotective effects in preclinical and early clinical studies. Ispronicline advanced to phase II clinical trials for Alzheimer's disease, age-associated memory impairment (AAMI), cognition disorders, and attention-deficit hyperactivity disorder (ADHD). However, development was discontinued after mid-stage trials failed to show sufficient efficacy. The drug was originally developed by Targacept (formerly a subsidiary of R.J. Reynolds Tobacco Company) in collaboration with AstraZeneca[2][3][4][5].

Other names

ispronicline